Silencing of 14-3-3ζ over-expression in hepatocellular carcinoma inhibits tumor growth and enhances chemosensitivity to cis-diammined dichloridoplatium

Cancer Letters

Volumn 303, Issue 2, 2011, Pages 99-107

  Choi, Jung Eun ^a   Hur, Wonhee ^a   Jung, Chan Kwon ^a   Piao, Lian Shu ^a   Lyoo, KwangSoo ^a   Hong, Sung Woo ^a   Kim, Sung Woo ^a   Yoon, Hye Yeon ^b   Yoon, Seung Kew ^a  

^a The Catholic University of Korea   (South Korea)

^b Ewha Womans University   (South Korea)

Author keywords

14 3 3 ; Cis diammined dichloridoplatium (CDDP); Gene therapy; Hepatocellular carcinoma; RNA interference (RNAi)

Indexed keywords

CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE P38; STRATIFIN; STRESS ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MITOSIS INHIBITION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; RNA INTERFERENCE;

14-3-3 PROTEINS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CISPLATIN; FLOW CYTOMETRY; GENE SILENCING; GENE THERAPY; HUMANS; LIVER NEOPLASMS; MAP KINASE KINASE 4; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 79952043084     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.01.015     Document Type: Article

References (28)

1. Block T.M., Mehta A.S., Fimmel C.J., Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003, 22(33):5093-5107.
2. Kogure T., Ueno Y., Iwasaki T., Shimosegawa T. The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother. Pharmacol. 2004, 53(4):296-304.
3. Okuda K., Tanaka M., Shibata J., Ando E., Ogata T., Kinoshita H. Et al., Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol. Rep. 1999, 6(3):587-591.
4. Toyoda H., Nakano S., Kumada T., Takeda I., Sugiyama K., Osada T. Et al., The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 1995, 52(4):295-299.
5. Ando E., Yamashita F., Tanaka M., Tanikawa K. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997, 79(10):1890-1896.
6. Aitken A. 14-3-3 proteins: a historic overview. Semin. Cancer Biol. 2006, 16(3):162-172.
7. Gardino A.K., Smerdon S.J., Yaffe M.B. Structural determinants of 14-3-3 binding specificities and regulation of subcellular localization of 14-3-3-ligand complexes: a comparison of the X-ray crystal structures of all human 14-3-3 isoforms. Semin. Cancer Biol. 2006, 16(3):173-182.
8. Hermeking H. The 14-3-3 cancer connection. Nat. Rev. Cancer 2003, 3(12):931-943.
9. van Hemert M.J., Steensma H.Y., van Heusden G.P. 14-3-3 proteins: key regulators of cell division, signalling and apoptosis. Bioessays 2001, 23(10):936-946.
10. Lehmann U., Langer F., Feist H., Glockner S., Hasemeier B., Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am. J. Pathol. 2002, 160(2):605-612.
11. Qi W., Martinez J.D. Reduction of 14-3-3 proteins correlates with increased sensitivity to killing of human lung cancer cells by ionizing radiation. Radiat. Res. 2003, 160(2):217-223.
12. Jang J.S., Cho H.Y., Lee Y.J., Ha W.S., Kim H.W. The differential proteome profile of stomach cancer: identification of the biomarker candidates. Oncol. Res. 2004, 14(10):491-499.
13. Matta A., Bahadur S., Duggal R., Gupta S.D., Ralhan R. Over-expression of 14-3-3zeta is an early event in oral cancer. BMC Cancer 2007, 7:169.
14. Morris K.V., Rossi J.J. Antiviral applications of RNAi. Curr. Opin. Mol. Ther. 2006, 8(2):115-121.
15. Zhang Z., Wang H., Li M., Rayburn E., Agrawal S., Zhang R. Novel MDM2 p53-independent functions identified through RNA silencing technologies. Ann. NY Acad. Sci. 2005, 1058:205-214.
16. Lee Y.C., Hur W., Choi J.E., Piao L.S., Hong S.W., Bae S.H., et al. Analysis of gene expression in primary hepatocellular carcinoma using differentially displayed reverse transcriptase polymerase chain reaction. Korean J. Gastroenterol. 2009, 53(6):361-368.
17. Park S.Y., Choi J.H., Ryu H.S., Pak Y.K., Park K.S., Lee H.K., et al. C1q tumor necrosis factor alpha-related protein isoform 5 is increased in mitochondrial DNA-depleted myocytes and activates AMP-activated protein kinase. J. Biol. Chem. 2009, 284(41):27780-27790.
18. Fan T., Li R., Todd N.W., Qiu Q., Fang H.B., Wang H., et al. Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target. Cancer Res. 2007, 67(16):7901-7906.
19. Neal C.L., Yao J., Yang W., Zhou X., Nguyen N.T., Lu J., et al. 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res. 2009, 69(8):3425-3432.
20. C.L. Neal, 14-3-3zeta overexpression in multiple human cancers plays a critical role in cancer progression, Texas Medical Center Dissertations, vol. 1, 2004, pp. 3171-3583.
21. Carr B.I. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004, 127(5 Suppl. 1):S218-S224.
22. Nishio K., Nakamura T., Koh Y., Suzuki T., Fukumoto H., Saijo N. Drug resistance in lung cancer. Curr. Opin. Oncol. 1999, 11(2):109-115.
23. Liu M.Y., Cai S., Espejo A., Bedford M.T., Walker C.L. 14-3-3 interacts with the tumor suppressor tuberin at Akt phosphorylation site(s). Cancer Res. 2002, 62(22):6475-6480.
24. Aitken A., Jones D., Soneji Y., Howell S. 14-3-3 proteins: biological function and domain structure. Biochem. Soc. Trans. 1995, 23(3):605-611.
25. Zhang Y., Huang Y., Rishi A.K., Sheikh M.S., Shroot B., Reichert U., et al. Activation of the p38 and JNK/SAPK mitogen-activated protein kinase pathways during apoptosis is mediated by a novel retinoid. Exp. Cell Res. 1999, 247(1):233-240.
26. Ichijo H., Nishida E., Irie K., Ten Dijke P., Saitoh M., Moriguchi T., et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997, 275(5296):90-94.
27. Sunayama J., Tsuruta F., Masuyama N., Gotoh Y. JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. J. Cell Biol. 2005, 170(2):295-304.
28. Sanchez-Perez I., Murguia J.R., Perona R. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 1998, 16(4):533-540.